Exact test-based approach for equivalence test with parameter margin
(Cassie) Dong, Xiaoyu, Bian, Yuanyuan, Tsong, Yi, Wang, Tianhua
Published in Journal of biopharmaceutical statistics (04.03.2017)
Published in Journal of biopharmaceutical statistics (04.03.2017)
Get full text
Journal Article
Brentuximab vedotin with chemotherapy in adolescents and young adults with stage III or IV classical Hodgkin lymphoma in ECHELON-1
Crosswell, Howland E, LaCasce, Ann S, Bartlett, Nancy L, Straus, David J, Savage, Kerry J, Zinzani, Pier Luigi, Collins, Graham P, Fanale, Michelle, Fenton, Keenan, Dong, Cassie, Miao, Harry, Grigg, Andrew P
Published in Haematologica (Roma) (01.03.2024)
Published in Haematologica (Roma) (01.03.2024)
Get full text
Journal Article
PB2351: TRIAL IN PROGRESS: A PHASE 2, MULTICENTRE STUDY OF BRENTUXIMAB VEDOTIN WITH CHEMOTHERAPY IN FRONTLINE TREATMENT OF CHINESE PATIENTS WITH CD30‐POSITIVE PERIPHERAL T‐CELL LYMPHOMAS
Song, Yuqin, Wu, Helen, Ji, Meng, Jiang, Wenhan, Dong, Cassie, Zhu, Jun
Published in HemaSphere (08.08.2023)
Published in HemaSphere (08.08.2023)
Get full text
Journal Article
Adjustment for unbalanced sample size for analytical biosimilar equivalence assessment
Dong, Xiaoyu (Cassie), Weng, Yu-Ting, Tsong, Yi
Published in Journal of biopharmaceutical statistics (04.03.2017)
Published in Journal of biopharmaceutical statistics (04.03.2017)
Get full text
Journal Article
P009: Improved Overall Survival with First‐Line Brentuximab Vedotin plus Chemotherapy in Patients with Advanced Stage III/IV Classical Hodgkin Lymphoma: An Updated Analysis of ECHELON‐1
Hutchings, Martin, Ansell, Stephen M., Connors, Joseph M., Kim, Won Seog, Gallamini, Andrea, Ramchandren, Radhakrishnan, Friedberg, Jonathan W., Advani, Ranjana, Evens, Andrew M., Smolewski, Piotr, Savage, Kerry J., Bartlett, Nancy L., Eom, Hyeon‐Seok, Abramson, Jeremy S., Dong, Cassie, Campana, Frank, Fenton, Keenan, Puhlmann, Markus, Straus, David J., Radford, John
Published in HemaSphere (03.10.2022)
Published in HemaSphere (03.10.2022)
Get full text
Journal Article
Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin’s Lymphoma
Ansell, Stephen M., Radford, John, Connors, Joseph M., Długosz-Danecka, Monika, Kim, Won-Seog, Gallamini, Andrea, Ramchandren, Radhakrishnan, Friedberg, Jonathan W., Advani, Ranjana, Hutchings, Martin, Evens, Andrew M., Smolewski, Piotr, Savage, Kerry J., Bartlett, Nancy L., Eom, Hyeon-Seok, Abramson, Jeremy S., Dong, Cassie, Campana, Frank, Fenton, Keenan, Puhlmann, Markus, Straus, David J.
Published in The New England journal of medicine (28.07.2022)
Published in The New England journal of medicine (28.07.2022)
Get full text
Journal Article
Abstract OT-28-01: HER2CLIMB-02: A randomized, double-blind, phase 3 study of tucatinib or placebo with T-DM1 for unresectable locally-advanced or metastatic HER2+ breast cancer
Hurvitz, Sara, Vahdat, Linda, Harbeck, Nadia, Wolff, Antonio C., Tolaney, Sara M., Loi, Sherene, Masuda, Norikazu, O’Shaughnessy, Joyce, Dong, Cassie, Walker, Luke, Rustia, Evelyn, Borges, Virginia F.
Published in Cancer research (Chicago, Ill.) (15.02.2021)
Published in Cancer research (Chicago, Ill.) (15.02.2021)
Get full text
Journal Article
The Echelon-2 Trial: 5-Year Exploratory Subgroup Analyses of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Vs CHOP in Frontline Treatment of Pts with CD30-Positive Peripheral T-Cell Lymphoma
Horwitz, Steven M., Savage, Kerry J., Illidge, Tim, Iyer, Swaminathan P, Advani, Ranjana, Shustov, Andrei R, Bartlett, Nancy L., Pro, Barbara, Jacobsen, Eric D, Koch, Raphael, Eva, Domingo Domenech, Fanale, Michelle A., Fenton, Keenan, Campana, Frank, Dong, Cassie, Truemper, Lorenz
Published in Blood (23.11.2021)
Published in Blood (23.11.2021)
Get full text
Journal Article
Phase 1 study to evaluate the effects of rifampin on pharmacokinetics of pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors
Zhou, Xiaofei, Vaishampayan, Ulka, Mahalingam, Devalingam, Harvey, R. Donald, Chung, Ki Young, Sedarati, Farhad, Dong, Cassie, Faller, Douglas V., Venkatakrishnan, Karthik, Gupta, Neeraj
Published in Investigational new drugs (01.10.2022)
Published in Investigational new drugs (01.10.2022)
Get full text
Journal Article
Abstract OT2-01-01: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with T-DM1 for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer
Hurvitz, Sara, Vahdat, Linda, Harbeck, Nadia, Wolff, Antonio C, Tolaney, Sara M, Loi, Sherene, Masuda, Norikazu, Dong, Cassie, Walker, Luke, Rustia, Evelyn, Borges, Virginia
Published in Cancer research (Chicago, Ill.) (15.02.2020)
Published in Cancer research (Chicago, Ill.) (15.02.2020)
Get full text
Journal Article
Brentuximab vedotin with chemotherapy in adolescents and young adults (AYAs) with stage III or IV Hodgkin lymphoma: A subgroup analysis from the phase 3 Echelon-1 study
Crosswell, Howland E., LaCasce, Ann S., Bartlett, Nancy L., Straus, David J., Savage, Kerry J., Zinzani, Pier Luigi, Collins, Graham P., Fanale, Michelle A., Fenton, Keenan, Dong, Cassie, Miao, Harry H., Grigg, Andrew
Published in Journal of clinical oncology (20.05.2021)
Published in Journal of clinical oncology (20.05.2021)
Get full text
Journal Article
First-line brentuximab vedotin plus chemotherapy to improve overall survival in patients with stage III/IV classical Hodgkin lymphoma: An updated analysis of ECHELON-1
Ansell, Stephen M., Connors, Joseph M., Radford, John A., Kim, Won Seog, Gallamini, Andrea, Ramchandren, Radhakrishnan, Friedberg, Jonathan W., Advani, Ranjana H., Hutchings, Martin, Evens, Andrew M., Smolewski, Piotr, Savage, Kerry J., Bartlett, Nancy L., Eom, Hyeon Seok, Abramson, Jeremy S., Dong, Cassie, Campana, Frank, Fenton, Keenan, Puhlmann, Markus, Straus, David J.
Published in Journal of clinical oncology (01.06.2022)
Published in Journal of clinical oncology (01.06.2022)
Get full text
Journal Article
HL-507 First-Line Brentuximab Vedotin Plus Chemotherapy Improves Overall Survival in Patients With Stage III/IV Classical Hodgkin Lymphoma: An Updated Analysis of ECHELON-1
Straus, David, Radford, John, Connors, Joseph, Kim, Won Seog, Gallamini, Andrea, Ramchandren, Radhakrishnan, Friedberg, Jonathan, Advani, Ranjana, Hutchings, Martin, Evens, Andrew, Smolewski, Piotr, Savage, Kerry, Bartlett, Nancy, Eom, Hyeon-Seok, Abramson, Jeremy, Dong, Cassie, Campana, Frank, Fenton, Keenan, Puhlmann, Markus, Ansell, Stephen
Published in Clinical lymphoma, myeloma and leukemia (01.10.2022)
Published in Clinical lymphoma, myeloma and leukemia (01.10.2022)
Get full text
Journal Article
Poster: HL-507 First-Line Brentuximab Vedotin Plus Chemotherapy Improves Overall Survival in Patients With Stage III/IV Classical Hodgkin Lymphoma: An Updated Analysis of ECHELON-1
Straus, David, Radford, John, Connors, Joseph, Kim, Won Seog, Gallamini, Andrea, Ramchandren, Radhakrishnan, Friedberg, Jonathan, Advani, Ranjana, Hutchings, Martin, Evens, Andrew, Smolewski, Piotr, Savage, Kerry, Bartlett, Nancy, Eom, Hyeon-Seok, Abramson, Jeremy, Dong, Cassie, Campana, Frank, Fenton, Keenan, Puhlmann, Markus, Ansell, Stephen
Published in Clinical lymphoma, myeloma and leukemia (01.10.2022)
Published in Clinical lymphoma, myeloma and leukemia (01.10.2022)
Get full text
Journal Article